androgen therapy
Recently Published Documents


TOTAL DOCUMENTS

372
(FIVE YEARS 71)

H-INDEX

38
(FIVE YEARS 2)

EBioMedicine ◽  
2022 ◽  
Vol 75 ◽  
pp. 103760
Author(s):  
Mone't B. Thompson ◽  
Daniel Muldoon ◽  
Kelvin C. de Andrade ◽  
Neelam Giri ◽  
Blanche P. Alter ◽  
...  

Author(s):  
Wout Devlies ◽  
Gaëtan Devos ◽  
Henri Decloedt ◽  
Bram Vansevenant ◽  
Frank Claessens ◽  
...  

2021 ◽  
pp. jnumed.121.262958
Author(s):  
Indulekha Singaravelu ◽  
Henry Spitz ◽  
Mary Mahoney ◽  
Zhongyun Dong ◽  
Nalinikanth Kotagiri

2021 ◽  
Vol 233 (5) ◽  
pp. S205-S206
Author(s):  
Jiaxi Chen ◽  
Vivian J. Hu ◽  
Edward C. Ray ◽  
Shikha Bose ◽  
Armando E. Giuliano
Keyword(s):  

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 1069
Author(s):  
Xavier Bonfill-Cosp ◽  
Ariadna Auladell-Rispau ◽  
Ignasi Gich ◽  
Javier Zamora ◽  
Luis Carlos Saiz ◽  
...  

Background: Although intermittent androgen deprivation therapy was introduced many years ago to improve patients’ quality of life with the same carcinologic efficiency as continuous hormonal therapy, recent data suggest that those patients could be overtreated. This study aims to estimate the prevalence of prostate cancer patients receiving intermittent androgen deprivation therapy in Spain. Methods: A retrospective, longitudinal study was conducted using electronic drug dispensation data from four Spanish autonomous communities, which encompass 17.23 million inhabitants (36.22% of the total population in Spain). We estimated intermittent androgen therapy use (%IAD) and the prevalence of patients under intermittent androgen therapy (PIAD) overall and stratified by region. Other outcome variables included the pharmaceutical forms dispensed and the total direct annual expenditure on androgen deprivation therapy‐associated medications. Results: A total of 863,005 dispensations corresponding to a total of 65,752 men were identified, treated with either luteinizing hormone-releasing hormone (LHRH) analogues (353,162) administered alone or in combination with anti‐androgens (509,843). Overall, the mean (±SD) age of the patients was 76.9 (±10.4) years. Results revealed that the mean annual PIAD along the study was 6.6% in the total population studied, and the overall %IAD during the five‐year study period was 5.6%. The mean cost of hormonal therapy per year was 25 million euros for LHRH analogues and 6.3 million euros for anti-androgens. Conclusions:  An important proportion of prostate cancer patients in Spain could benefit from intermittent androgen therapy during the study period while avoiding overtreatment harms associated with continuous hormonal therapy.


2021 ◽  
Vol 11 (9) ◽  
pp. 484-490
Author(s):  
Sylwiusz Niedobylski ◽  
Katarzyna Laszczak ◽  
Konrad Warchoł ◽  
Sara Moqbil ◽  
Karolina Kalicka

Introduction and purpose: Prostate cancer (PCa) as one of the most frequent neoplasms in men remains a challenge for oncologists. The main strategy of its treatment is the Androgen Deprivation Therapy (ADT) the principle of which is an inducement of hypogonadism. The lack of testosterone is not only a factor greatly contributing to a decrease of quality of life overall, but additionally it increases the odds of the complications, including low libido and erectile disfunction, metabolic abnormalities, high cardiovascular risk, osteoporosis, anaemia, or depression. ADT also has the potential of inducement of castration resistance (CRPC), which significantly worsen patients prognosis. The main purpose of this review is to explore the Bipolar Androgen Therapy (BAT), which has the potential to solve the aforementioned problems. State of knowledge: The mechanism of BAT action has been described. BAT is effective not only against CRPC, but androgen-dependant PCa as well. BAT reverses the hormone resistance in CRPC, thus allowing the rechallenging of the ADT. It has the direct cytotoxic effect on cancer cells. Additionally BAT increases the exponents of the general quality of life of the patients. There is a number of active clinical trials regarding BAT. Conclusions: BAT is a safe therapeutic strategy with the high efficacy in reversing hormone resistance in CRPC patients, thus significantly increasing their health prognoses and it allows to alleviate or avoid the adverse effects of ADT.


2021 ◽  
Vol 32 ◽  
pp. S639-S640
Author(s):  
M. Schweizer ◽  
R. Gulati ◽  
T. Yezefski ◽  
H. Cheng ◽  
C. Sievers ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document